Brian C. Stephenson - 03 Dec 2021 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Title: Secretary, Treasurer and Chief Financial Officer
Signature
Yi Ching Yau, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
03 Dec 2021
Net transactions value
$0
Form type
4
Filing time
07 Dec 2021, 17:05:06 UTC
Previous filing
18 Nov 2021
Next filing
18 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (right to buy) Award $0 +211,366 $0.000000 211,366 03 Dec 2021 Common Stock 211,366 $38.62 Direct F1
transaction BBIO Restricted Stock Units Award $0 +15,144 $0.000000 15,144 03 Dec 2021 Common Stock 15,144 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable as to 25% of the underlying shares on December 3, 2022 and thereafter in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The RSUs will vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Remarks:

Title: Secretary, Treasurer and Chief Financial Officer